Phaseline

Companies › Jubilant Therapeutics India

Jubilant Therapeutics India: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JBI-778
Selective PRMT5 inhibitor
PRMT5Phase 1NSCLC Patients With EGFR Activating MutationMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07755397JBI-778Phase 1NSCLC Patients With EGFR Activating MutationOncologyMar 2028

Targets

PRMT5 (1)

Companies with the same targets

Bristol-Myers Squibb Tango Therapeutics Bayer IDEAYA Biosciences Amgen Jiangsu Simcere Pharmaceutical AstraZeneca PharmaEngine Servier Bio-Innovation

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.